Dr Marco Herold-Lab Team

Dr Marco Herold-Lab Team

In addition to our research on BCL-2 family proteins, my laboratory is responsible for setting up new genome editing technology within the Institute. This is being used for the production of new in vivo models as well as a whole genome screening platform.

Andrew Kueh, Postdoctoral Fellow, BSc(Hons) MB BS PhD Melbourne
Project: Development of CRISPR/Cas9 technology for generating mutant mice
Key publication: Kueh AJ, Herold MJ. Using CRISPR/Cas9 technology for manipulating cell death regulators. Methods Mol Biol. 2016 1419:253-64. PMID: 27108444

Martin Pal, Postdoctoral Fellow, PhD Cologne
Project: Development of CRISPR/Cas9 technology for generating mutant mice

Margs Brennan, PhD Student, BSc (Hons) Melbourne
Project: Characterising an MCL-1 inhibitor for the treatment of lymphoma
Key Paper: Lang MJ, Brennan MS, O'Reilly LA, Ottina E, Czabotar PE, Whitlock E, Fairlie WD, Tai L, Strasser A, Herold MJ. Characterisation of a novel A1-specific monoclonal antibody. Cell Death Dis. 2014 Dec 4; 5:e1553. PMID: 25476901

Ranja Salvamoser, PhD Student, MSc LMU Munich
Project: Analysing the impact of deleting CARD containing caspases on different forms of cell death

Robyn Schenk, PhD Student, BSc(Hons) Canterbury
Project: Determining the role of the pro-survival Bcl-2 family member A1 in lymphoma and leukaemia

Lin Tai, Research Assistant, BAppSc Swinburne MSc La Trobe